Investigational · not FDA approved

Editorially reviewed · Last updated July 24, 2026 · How we review

TB-500: FDA 503A Vote, Legality & Evidence

Key findings

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6-1 to recommend adding TB-500 to the 503A Bulks List — the same margin given to BPC-157 and KPV.
The vote is advisory and non-binding. TB-500 is not legal to prescribe or compound today; the FDA must still complete rulemaking, estimated at 12-24 months (into 2027 or beyond).
The committee overruled the FDA's own staff, whose case against TB-500 was stronger than for BPC-157 — no human effectiveness data, a cited in-vitro study where TB-500 failed to induce wound healing, immunogenicity risk, and poor chemical characterization.
TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4. The advanced human trials people cite involve full-length thymosin beta-4 as a topical eye drop (RGN-259) — a different molecule and use.
There is no completed human efficacy trial for TB-500 in injury or musculoskeletal recovery, and no validated human dose.
TB-500 is banned in sport at all times under WADA and is sold today only as an unapproved 'research chemical' on the grey market.

TB-500: The FDA 503A Vote, Legality, and What the Evidence Actually Shows

Q: What is the difference between TB-500 and thymosin beta-4?

TB-500 is a synthetic 17-amino-acid fragment; thymosin beta-4 (Tβ4) is the full 43-amino-acid protein. They are not interchangeable in the evidence: the most advanced human trials involve full-length Tβ4 as a topical eye drop for dry eye (RGN-259), not injected TB-500 for tissue recovery.

TB-500 is not an FDA-approved drug and is not legal to prescribe or compound in the United States today. This page explains a fast-moving regulatory story and the state of the evidence for educational purposes only. It is not medical advice, a recommendation, or encouragement to obtain, supply, or use any substance. Consult a qualified healthcare provider for any medical decision.

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend that TB-500 be added to the 503A Bulks List — the same margin it gave BPC-157 earlier that day. With both votes in, one peptide influencer summed up the mood: "both halves of the Wolverine Stack made it through the panel."

But the same correction that applied to BPC-157 applies here, and it matters even more for TB-500: eligible is not the same as legal. The committee's "yes" overruled the FDA's own scientists — and for TB-500, the staff's case against it was notably stronger than for BPC-157. This page covers what the vote does and doesn't do, what TB-500 actually is, and why the evidence is thinner than the enthusiasm.

The TB-500 Vote: What Actually Happened

Detail	What the record shows
Vote	8 in favor, 6 against, 1 abstention
Body	FDA Pharmacy Compounding Advisory Committee (PCAC)
Date	July 23, 2026
Question	Add TB-500 (free base + acetate) to the 503A Bulks List?
Indication reviewed	Wound healing
FDA staff position	Recommended against — no human effectiveness data, plus safety and characterization concerns
Committee outcome	Overruled staff and voted to recommend inclusion
Binding?	No — advisory only

Like BPC-157 and KPV, TB-500 cleared the committee 8–6–1 despite the FDA staff recommending "no" on all seven peptides under review. What sets TB-500 apart is why the staff said no — the objections went beyond "thin data":

No human effectiveness data for the wound-healing use it was nominated for.
A cited in-vitro study in which TB-500 did not induce wound healing in fibroblast cultures — a negative result, not just an absence of evidence.
Immunogenicity risk from peptide aggregation and impurities in injectable products, with no data showing TB-500 avoids it.
Poor chemical characterization — the FDA found both the free-base and acetate forms are not well characterized, citing inconsistent naming conventions (INN, USAN, IUPAC) and missing data specific to each form.

The committee weighed all that and still recommended inclusion. That gap — between what the evidence shows and what the vote recommends — is the story.

Eligible Does Not Mean Legal

A PCAC recommendation does not make TB-500 legal. The pathway is identical to BPC-157's:

Step	Status	Meaning
Removed from Category 2	Done (2026)	No longer explicitly flagged as significant-risk — but not authorized
PCAC advisory vote	Done (Jul 23, 2026, 8–6)	The committee recommends adding it. Non-binding.
FDA proposed rule	Not started	The FDA must publish a proposed rule to add it to the 503A list
Public comment period	Not started	Notice-and-comment rulemaking, typically many months
Final rule	Not started	Only after this can pharmacies legally compound it — estimated 12–24 months out, into 2027 or beyond

Nothing changed about what you can legally buy the week of the vote. The FDA can still decline the recommendation, and given how pointed its staff's objections to TB-500 were, that outcome is far from ruled out. Today, TB-500 remains an unapproved substance sold only as a "research chemical."

Is TB-500 Legal Right Now?

Question	Answer as of July 2026
Is it FDA-approved?	No. It has never been approved as a drug for any use.
Can a pharmacy legally compound it?	No — not until the FDA completes rulemaking to add it to the 503A list.
Can a doctor prescribe it?	No approved product exists to prescribe.
Is it sold online?	Yes — labeled 'for research use only, not for human consumption.'
Is it allowed in sport?	No. TB-500 is on the WADA Prohibited List (banned at all times); athletes have been sanctioned.
When might it be legally compounded?	If the FDA finalizes a rule — estimated 12–24 months away, with no guaranteed outcome.

What Is TB-500?

TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4 (Tβ4), a naturally occurring protein involved in cell migration, blood-vessel formation, and tissue repair. It is marketed for systemic recovery — tendons, ligaments, muscle, and flexibility — usually by subcutaneous or intramuscular injection.

An important distinction the seller pages tend to blur:

Substance	What it is	Clinical development
TB-500	A synthetic 17-amino-acid fragment of thymosin beta-4	No completed human efficacy trial for the injury-recovery use case
Full-length thymosin beta-4 (Tβ4)	The complete 43-amino-acid protein	Has reached Phase 2/3 — but for a topical eye drop (RGN-259, dry eye), not injected muscle recovery

So when a marketing page cites "thymosin beta-4 clinical trials," it is usually pointing at the eye-drop program for a different molecule — not evidence that injected TB-500 heals tendons.

The Evidence: Animal vs Human

Evidence type	What exists
Animal studies	Preclinical data on Tβ4 and fragments in cardiac, wound, and tissue-repair models
Published human RCTs	None. No completed human efficacy trial for musculoskeletal injury
Human effectiveness data for the reviewed use	None, per the FDA's own review
A cited in-vitro test	TB-500 did not induce wound healing in fibroblast cultures
Chemical characterization	FDA found both forms poorly characterized (naming and data gaps)
Long-term human safety data	Essentially none

The honest read: TB-500's human evidence is weaker than BPC-157's, not stronger. BPC-157 at least has an unpublished Phase 2 ulcerative-colitis signal and a large body of positive animal work; TB-500's file includes a specific negative in-vitro result and unresolved characterization and immunogenicity questions. That is exactly why the FDA staff's objection here was more forceful — and why the 8–6 committee vote is better read as "the risk seems low enough to allow" than "the science is settled."

Why the FDA Said No but the Committee Said Yes

This is the crux, and it mirrors the wider peptide debate. The FDA staff apply a drug-evaluation standard: show effectiveness and safety with quality data. By that bar, TB-500 fails. The committee majority applied a lighter compounding-access standard: is the substance reasonably characterizable and the risk low enough that a prescriber and pharmacy should have the option? Enough members answered yes.

Neither answer means TB-500 "works." It means the committee thought it belonged on a list of things pharmacies may compound if the FDA agrees — which the FDA has not yet done.

Doses Circulating in the Community (No Clinical Validation)

As with BPC-157, search demand for "TB-500 dosage" is high, so let's be direct: there is no validated human dose of TB-500, because no completed human trial has established one. Any protocol is extrapolated from animal work and grey-market convention.

For transparency, the figures that circulate look like this — shown only to describe the phenomenon, not as guidance:

Reported community practice	Typical figure cited	Reality check
Loading phase	~2–2.5 mg, twice weekly for 4–6 weeks	No trial basis; vial concentrations are frequently wrong
Maintenance	~2–2.5 mg, once weekly or less	Not studied; no established course
Route	Subcutaneous or intramuscular injection	Unregulated products; sterility not guaranteed
Stacked with	BPC-157 (the 'Wolverine stack')	The combination has no human data whatsoever

Because these are sold as research chemicals, the reconstitution math is the buyer's, the labeled dose may not match the vial, and there is no quality control. This is not a validated protocol — it is a description of a risk.

Grey-Market Safety Risks

Until (and unless) the FDA finalizes a rule, every TB-500 vial for sale is an unapproved product outside the drug-safety system:

Immunogenicity. The FDA specifically flagged that injected peptides can trigger immune reactions from aggregation and impurities, and that TB-500 has no data ruling this out.
Contamination and mislabeling. Third-party testing of research peptides routinely finds wrong contents, incorrect quantities, and bacterial contamination.
Reconstitution error. A decimal-place mistake in freeze-dried peptide math changes the dose tenfold.
Sport eligibility. TB-500 and thymosin beta-4 are prohibited at all times under WADA; athletes have been sanctioned.
"Not for human use" labeling. That disclaimer is a warning, not a technicality.

See the site's standing guidance on grey-market peptides and gray-market retatrutide.

TB-500 vs BPC-157

The two are almost always mentioned together, and both cleared the July 2026 PCAC vote 8–6–1. A quick orientation:

	TB-500	BPC-157
What it is	17-aa fragment of thymosin beta-4	15-aa 'body protective compound'
Marketed for	Systemic soft-tissue recovery	Gut and tissue healing
Human RCT evidence	None (a negative in-vitro result cited)	None (unpublished Phase 2 UC signal)
503A vote (Jul 2026)	Recommended 8–6–1	Recommended 8–6
Legal to compound today?	No	No
WADA status	Banned at all times	On the prohibited list

For the full breakdown of BPC-157, see the BPC-157 explainer.

The "Wolverine Stack"

TB-500 and BPC-157 combined are what the peptide community calls the "Wolverine stack" — a nod to comic-book healing. Both halves cleared the FDA committee on the same day, which is why the phrase trended. But the combination has zero human data — stacking two unapproved peptides multiplies the unknowns rather than the benefit. We break down the stack, the circulating "blend" ratios, and why a pre-mixed BPC/TB vial is riskier, not safer, in the Wolverine stack explainer.

How This Relates to GLP-1 Drugs and Retatrutide

TB-500 is a recovery peptide, not a weight-loss drug — it does not act on the GLP-1, GIP, or glucagon receptors that retatrutide and other GLP-1 medications target. The overlap is regulatory and behavioral: the same 503A pathway now debated for TB-500 is the one that made compounded semaglutide available, and TB-500 is commonly stacked alongside GLP-1s to manage joint and soft-tissue complaints during rapid weight loss. See Are Peptides Legal in 2026? for the wider picture.

Unlike TB-500, retatrutide's evidence comes from large published Phase 2 and Phase 3 trials — the two should not be judged by the same standard of proof.

Frequently Asked Questions

Did the FDA approve TB-500?

No. On July 23, 2026, the FDA's advisory committee (PCAC) voted 8–6 (one abstention) to recommend adding TB-500 to the 503A compounding list — overruling the FDA's own staff, who recommended against it. That is an advisory recommendation, not approval and not a rule. TB-500 has never been FDA-approved, and it is still not legal to compound or prescribe. Formal rulemaking is estimated to take 12–24 months.

Is TB-500 legal now?

Not for prescribing or compounding. The advisory vote does not change the law. Until the FDA finalizes a rule adding TB-500 to the 503A Bulks List, it remains an unapproved substance sold only as a "research chemical, not for human consumption." It is also banned in sport under WADA.

Is there any human evidence that TB-500 works?

No completed human efficacy trial supports TB-500 for injury or musculoskeletal recovery. The FDA's review found no human effectiveness data and cited an in-vitro study in which TB-500 did not induce wound healing. Clinical trials that people point to usually involve full-length thymosin beta-4 as a topical eye drop (RGN-259) — a different molecule and a different use.

Why did the committee vote yes if the FDA staff said no?

The two groups apply different standards. FDA staff evaluate effectiveness and safety with drug-grade data, and by that bar TB-500 falls short. The committee majority judged that the substance is characterizable enough and the risk low enough that prescribers and pharmacies should have the option to compound it — if the FDA agrees. A yes vote is not a finding that TB-500 works.

What is the correct dose of TB-500?

There is no established human dose, because no completed human trial has determined one. Community protocols (often cited as roughly 2–2.5 mg twice weekly for a few weeks, then less) are extrapolated from animal work, not clinical evidence — and because grey-market vials are frequently mislabeled or mis-concentrated, even those figures cannot be relied on.

What is the difference between TB-500 and thymosin beta-4?

TB-500 is a synthetic 17-amino-acid fragment; thymosin beta-4 (Tβ4) is the full 43-amino-acid protein. They are not interchangeable in the evidence: the most advanced human trials involve full-length Tβ4 as a topical eye drop for dry eye (RGN-259), not injected TB-500 for tissue recovery.

What is the Wolverine stack?

It's the community nickname for combining TB-500 with BPC-157 — a reference to fast healing. Both peptides cleared the July 2026 FDA committee vote on the same day, which is why the term trended. The combination has no human data, and mixing two unapproved peptides increases the unknowns. See the Wolverine stack explainer.

Is TB-500 safe?

Its safety in humans is not established. The FDA flagged immunogenicity risk from injected-peptide aggregation and impurities, and grey-market products are frequently mislabeled or contaminated. There is essentially no long-term human safety data. "Research use only" on the label is a warning, not a reassurance.

Sources

U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov meeting page
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 list). FDA.gov
World Anti-Doping Agency. 2026 Prohibited List (TB-500 / thymosin beta-4, Section S2). WADA
Related on this site: BPC-157 · The Wolverine Stack · Are Peptides Legal in 2026? · Grey-Market Peptides

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

FDA PCAC July 23-24, 2026 meeting
FDA.gov
WADA Prohibited List
WADA

Grounded in primary sources

NEJM

The Lancet

JAMA

FDA

ClinicalTrials.gov

BPC-157: FDA 503A Vote, Legality & Safety

The FDA panel backed BPC-157 for compounding 8-6 — but eligible isn't legal. The vote, the 2027 timeline, the evidence gap, and why Hims stock jumped.

Explainer

The Wolverine Stack: BPC-157 + TB-500

Both halves of the 'Wolverine stack' passed the FDA panel — but the combination has zero human data. What the BPC-157 + TB-500 stack is, and why a pre-mixed blend is riskier, not safer.

Explainer

Are Peptides Legal in 2026? The FDA Reclassification Explained

The FDA's advisory committee recommended six of seven peptides on July 23-24, 2026 — against its own scientists. Why recommended still is not legal, and what it means for weight loss drugs.

Safety

Grey Market Retatrutide: Risks, Dangers, and What You Should Know

Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.

Guide

Retatrutide Cost & How to Get It

What retatrutide might cost, how to access it through clinical trials, and why gray market peptides are dangerous.